SCOTTSDALE, Ariz., July 1, 2015 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a specialty pharmaceutical company developing FDA-approved prescription drugs and FDA-regulated medical foods, today announced the election of Joseph J. Krivulka and Martin A. Simonetti to its Board of Directors.
Commenting on the election of these new independent Board members, Peter Moriarty, Chairman and CEO of Prismic, stated, "We are delighted that Joe Krivulka and Martin Simonetti have accepted our invitation to join Prismic's Board of Directors. They bring exceptional talent and vast experience of the ethical pharmaceutical industry, and will provide our Board with additional key strengths and expertise as we take the next distinct step in the development of Prismic Pharmaceuticals."
"Joe Krivulka is a highly experienced pharmaceutical executive and successful entrepreneur. He was a Founder and President of Reliant Pharmaceuticals which was subsequently acquired by GSK (GlaxoSmithKline), and Triax Pharmaceuticals which was sold to PreCision Dermatology. Mr. Krivulka is currently the Chairman of three other highly successful pharmaceutical companies, Akrimax, Rouses Point, and Mist Pharmaceuticals, all of which he was the Founder. Earlier in his career, Mr. Krivulka was the Chief Executive Officer of Bertek, Inc., a subsidiary of Mylan Inc., and a Corporate Vice President of Mylan Inc."
Moriarty went on to comment that, "Martin Simonetti brings expertise in both science and finance, having started his career in the field of medicinal and analytical chemistry at Genentech before receiving his MBA and moving into the finance and operations area. He is a former Vice President of Operations and Finance at Amgen BioPharma, and, through 2005, was the Chief Financial Officer, Senior Vice President of Finance and Treasurer at Dendreon Corporation, a company focused on the development of cancer treatments. More recently, Mr. Simonetti served as President and Chief Executive Officer of VLST Corporation, a Seattle-based biotechnology company. He is currently a member of the Board of Directors of EpiThany, Inc. and the Executive Chairman of Nexgenia, Inc."
Both Mr. Krivulka and Mr. Simonetti have extensive experience serving on Boards of both private and public companies, including chairing Compensation and Audit Committees, respectively.
About Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company developing highly differentiated proprietary products in two distinct FDA categories, Prescription Drugs and Prescription Medical Foods, based on its two lead pharmaceutically active ingredients, ultra-micronized palmitoylethanolamide, and ultra-pure, high EPA, Omega-3. The company is developing products to address three key therapeutic areas with very large patient populations, and where there are clear and significant unmet clinical needs, namely, chronic kidney disease, depression, and severe chronic pain.
Contact 480.422.1810 or visit www.PrismicPharma.com.
Peter J. Moriarty
SOURCE Prismic Pharmaceuticals, Inc.